1997: Genentech begins clinical trials of Avastin on cancer patients.

February 2004: FDA approves Avastin to treat colon cancer.

October 2006: FDA approves Avastin to treat lung cancer.

December 2007: Advisory committee votes 5-4 against FDA approval of Avastin for breast cancer treatment.

February 2008: FDA ignores recommendation, grants accelerated temporary approval for use of Avastin in treating breast cancer.

May 2009: FDA approves Avastin to treat brain cancer.

July 2009: FDA approves Avastin to treat kidney cancer.

July 20, 2010: Advisory committee votes 12-1 against permanent FDA approval for use of Avastin against breast cancer.

Sept. 17: The FDA is scheduled to make a final decision on use of Avastin as a breast cancer treatment.